Earnings call transcript: STAAR Surgical misses Q1 2025 EPS forecast, stock dips
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed significant challenges: a massive decline in sales, especially in China, and a drop in gross margin. Despite some optimism about future demand and cost optimization, the withdrawal of guidance due to economic uncertainty and competitive pressures add to investor concerns. The lack of a shareholder return plan and refusal to provide clear guidance further dampen sentiment. Given the small market cap, these factors are likely to result in a negative stock price movement over the next two weeks.
Key Financial Performance
Total Net Sales $42,600,000, down from $77,400,000 (year-over-year change: -45%) due to minimal purchases by China distributors consuming existing inventory, partially offset by positive global sales growth outside of China.
China Sales $389,000, down from $38,500,000 (year-over-year change: -99%) as distributors consumed existing inventory instead of ordering from the company.
Net Sales Excluding China $42,200,000, representing a 9% increase year-over-year, driven by growth in APAC sales outside China.
Adjusted EBITDA Loss of $26,400,000, compared to earnings of $5,300,000 in the year-ago quarter (year-over-year change: -$31,700,000) primarily due to a $33,000,000 decrease in gross profit.
Gross Margin 65.8%, down from 78.9% (year-over-year change: -13.1%) due to higher manufacturing costs per unit and increased excess and obsolete inventory reserves.
Operating Expenses $62,700,000, down from $63,300,000 (year-over-year change: -$574,000) as the company implements cost savings initiatives.
Cash Balance $222,800,000 as of 03/28/2025, with a 38% year-over-year reduction in accounts receivable.
SG&A Run Rate Expected to be approximately $225,000,000, indicating a focus on cost optimization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EVO Plus Lens Launch: The EVO Plus lens technology, also known as V5, is on track for approval in China, expected later this summer. This is the first new lens in the market in over ten years.
China Market Recovery: End market demand in China is improving, with expectations of normalized sales beginning in Q3 2025. First quarter reported sales in China were $389,000, a significant drop from $38.5 million year-over-year, but the company is optimistic about future growth.
Global Market Positioning: The company is well-positioned to capture market share due to the growing prevalence of myopia and increasing demand for premium procedures in emerging markets.
Cost Optimization Initiatives: The company has identified actions to reduce costs, including personnel reductions and marketing savings, targeting an SG&A run rate of approximately $225 million by the end of 2025.
Management Restructuring: Streamlined management structure with new appointments, including Warren Faust as President and Deborah Andrews as Interim CFO, to enhance operational efficiency.
Tariff Mitigation Strategies: Negotiated consignment agreements to mitigate tariff impacts, allowing inventory to be held by distributors in China while remaining on the company's books.
Manufacturing Expansion: Plans to increase production capacity in Switzerland to support future growth and mitigate tariff risks, with expectations to manufacture over 300,000 lenses annually by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Risks: The company has faced challenges due to retaliatory tariffs imposed by China on U.S. goods. To mitigate this, STAAR Surgical negotiated consignment agreements and shipped consigned inventory to distributors in China, which is expected to alleviate tariff impacts through at least early 2026.
Supply Chain Challenges: The company is managing inventory levels with distributors in China to align revenue with in-market procedure volume. There is a concern about the ability to maintain adequate inventory levels if market demand does not recover as expected.
Economic Uncertainty: The company withdrew its previous guidance due to global economic uncertainty and evolving tariff policies, which complicate forecasting. The management expressed caution regarding the ability to meet previous revenue expectations.
Competitive Pressures: The introduction of new competitors in the ICL market, such as Ibrite, has been noted, but the impact on STAAR's sales has been minimal so far. The management remains optimistic that increased competition will raise overall market awareness.
Cost Management: STAAR Surgical is implementing cost-cutting measures, including reducing underutilized facilities and personnel, to improve long-term profitability. Restructuring charges have been incurred to rightsize the business.
Market Demand: Despite recent challenges, the company is optimistic about the growing demand for ICL procedures, particularly in China, where they expect a strong recovery in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Management Restructuring: Streamlined management structure to enhance effectiveness and efficiency, promoting Warren Faust to President and bringing back Deborah Andrews as Interim CFO.
Cost Optimization: Identified actions to reduce costs, targeting an SG&A run rate of approximately $225 million by the end of 2025.
Inventory Management: Working with distributors in China to manage inventory levels to align Q3 revenue with in-market procedure volume.
Manufacturing Expansion: Increasing production capacity in Switzerland to support future growth and mitigate tariff impacts.
EVO Plus Lens Launch: EVO Plus lens technology is on track for approval in China, expected later this summer.
Revenue Expectations: Withdrew previous guidance due to economic uncertainty but expressed confidence in achieving $165 million to $175 million in revenue excluding China.
China Revenue Outlook: Expecting to hit $75 million to $125 million in revenue from China.
Gross Margin Target: Targeting a gross margin of 70% in the second half of 2025, with long-term expectations of 75% to 80%.
Cash Position: Expecting cash to not drop below $140 million by year-end.
Adjusted EBITDA: Guided to approximately $30 million loss, with a current loss of $26.4 million in Q1.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: The company has not announced any specific share buyback or dividend program during the call. However, they mentioned a commitment to driving shareholder value through cost optimization and strategic growth initiatives.
Cost Optimization: The company is implementing cost-saving measures, targeting an SG&A run rate of approximately $225 million by the end of 2025.
Cash Position: STAAR Surgical ended the first quarter with $222.8 million in cash and expects to maintain a cash balance above $140 million through the year.
Future Cash Generation: The company anticipates returning to profitability and cash generation in the second half of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on how ICL sellout tracked in 1Q ’25?
A:We’re pleased with how the year started, particularly coming out of the back half of 2024 that was soft. The pace of January, February versus March were all fairly constant.
Q:What are your customers saying about Ibrite and its competitive impact on ICL?
A:It’s been quiet. We’ve asked our customers about it, and while some have had experience with it, it has been immaterial thus far.
Q:Does the current picture seem better than what was expressed by Star in February?
A:Yes, we’re making good progress on the cost side and mitigating our tariff issue, but we don’t know exactly what target we’re trying to hit.
Q:Can you quantify how much inventory there is in the channel in consignment?
A:We have enough inventory to mitigate tariffs through about the end of the year into 2026.
Q:What is the latest thinking on Visian ICL pricing in China and the U.S.?
A:No major changes. We believe in the value of the product and will continue to look at levers to unlock growth.
Q:How do you think about the go-to-market strategy in the U.S.?
A:We’re proud of what we’ve done in the U.S. and will continue to focus on helping our customers be clinically and economically confident.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific quantification of inventory levels in the channel and the exact impact of competition from Ibrite on revenue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO STAAR
COO STAAR
Farrell CEO
Faust President
Mizuho Group
President COO
SG level
Star
Stephen
Surgical Farrell
Surgical Vice
Surgical pace
Surgical questioner
Switzerland
Wells Fargo
approach
approval
chance
consignment
cost
cut
discussion
effort
end month
ex China
follow Faust
inventory China
inventory level
perspective
position
pricing
resource
shot
standpoint
tariff
thing
thinking
trust
value
STAA Transcript
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call revealed strong financial performance and optimistic product development, especially with EVO+. However, management's reluctance to provide guidance, coupled with macroeconomic uncertainties and potential margin pressures, tempers enthusiasm. The Q&A highlighted analysts' concerns about revenue targets and competitive pressures, but management remained optimistic about market stability and growth, particularly in China. The market cap suggests moderate volatility, but without clear guidance or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment rating.
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings report presents mixed signals: a 12% revenue increase and a 7% net income rise are positive, but the 1.5% decline in gross margin and lack of strategic or shareholder return updates are concerning. With a market cap of $2.3 billion, the stock is likely to have a muted reaction, placing it in the neutral range (-2% to 2%).
STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript
Unknown5-7
The earnings report shows significant declines in net sales and gross margin, especially in China, and an EBITDA loss. The Q&A reveals management's unclear responses regarding competition impact and withdrawn guidance, causing analyst concern. Despite some positive developments in ICL sales and market strategy, the lack of a share repurchase program and restructuring charges further weigh negatively. Given the market cap, the negative aspects are likely to outweigh the positives, leading to a negative stock price reaction.
Earnings call transcript: STAAR Surgical misses Q1 2025 EPS forecast, stock dips
Unknown5-7
The earnings call revealed significant challenges: a massive decline in sales, especially in China, and a drop in gross margin. Despite some optimism about future demand and cost optimization, the withdrawal of guidance due to economic uncertainty and competitive pressures add to investor concerns. The lack of a shareholder return plan and refusal to provide clear guidance further dampen sentiment. Given the small market cap, these factors are likely to result in a negative stock price movement over the next two weeks.
STAA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
